EXICURE, INC. (XCUR)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-10

Key Insights

Exicure, Inc. appointed Yoontae Han to its Board of Directors and Dongho Lee as Chair of the Audit Committee, strengthening the company's governance and oversight.
The company appointed Young Seung Ko as its new Chief Operating Officer, bringing over 20 years of experience in enterprise software, data infrastructure, and public company operations.
Exicure amended its executive services agreement with Innocircle Advisors to include the services of the Chief Operating Officer, potentially indicating an increased focus on operational execution.

Current Report Filed: 2026-03-27

Key Insights

Sangjin Yeo has resigned from Exicure's Board of Directors and Audit Committee, effective March 27, 2026. This resignation does not appear to be due to any disagreements with the company's operations, policies or practices.
The departure of a board member could signal potential changes in the company's leadership or strategic direction, which may impact investor sentiment.
Investors should monitor any further developments or announcements related to Yeo's resignation and any potential implications for Exicure's future.

Current Report Filed: 2026-03-25

Key Insights

Exicure, Inc. announced its financial and operational results for the year ended December 31, 2025, as disclosed in the press release.
The company's performance during this period may be of interest to investors and could impact the stock price.
Investors should review the press release and financial statements for further details on the company's financial condition and operations.

Annual Report Filed: 2026-03-25

Key Insights

EXICURE, INC. (XCUR) filed its annual 10-K report for the fiscal year 2025, providing a comprehensive overview of the company's financial performance and key developments.
The filing highlights EXICURE's ongoing research and development efforts in the GPCR USA program, including a license and collaboration agreement signed in 2025.
The company reported accrued liabilities of $0.0208 million as of December 31, 2025, a decrease from the previous year's $0.0277 million, indicating prudent financial management.

Current Report Filed: 2026-01-22

Key Insights

Exicure, Inc. achieved the first contractual milestone under its License and Collaboration Agreement with GPCR Therapeutics Inc., receiving a $1 million payment for completing a Phase 2 clinical trial of its novel stem cell mobilizer.
The milestone achievement reflects continued progress in the development and advancement of the small molecule CXCR4 inhibitor, Burixafor (GPC-100), and triggers a future sublicensing income-sharing ratio, indicating increased participation and commitment to the long-term success of the program.
The 8-K filing provides transparency on a significant operational milestone, which could positively impact investor sentiment and the company's future financial performance.

Insider Trading Filed: 2026-01-21

Key Insights

Exicure HiTron Inc., a 10% owner, sold 258,367 shares of EXICURE, INC. (XCUR) at $4.5 per share on 2026-01-21, reducing its direct ownership to 1,598,947 shares.
The sale of a significant number of shares by a major shareholder could signal a change in sentiment or outlook for the company.
Investors should monitor any further changes in insider ownership and trading patterns to gauge potential shifts in the company's prospects.

Insider Trading Filed: 2026-01-20

Key Insights

Exicure HiTron Inc., a 10% owner of Exicure, Inc. (XCUR), has sold 734,747 shares of the company's common stock at $4.5 per share, reducing its beneficial ownership to 1,857,314 shares.
The transaction suggests a change in the insider's position and potential investment strategy regarding Exicure, Inc.
Investors should monitor any further changes in insider ownership and trading patterns to gauge the potential impact on the company's performance and shareholder value.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.